SPHK2 and hepatocellular carcinoma: Particularly, previous observations have revealed an additive effect of the selective sphingosine kinase 2 (SPHK2) inhibitor ABC294640 together with sorafenib on cell toxicity and death in HCC cells in vitro and the increased suppression of tumor growth in murine HCC models [15].